CD44 and head and neck squamous cell carcinoma: Another study has indicated that afatinib (a second-generation tyrosine kinase inhibitor) reduces the self-renewal and invasive properties of HNSCC CSCs in culture by downregulating CD44 and OCT4, inhibiting tumor sphere formation and growth, and inducing radiosensitization [171].